Adma Biologics (ADMA) EBIT Margin (2011 - 2026)
Adma Biologics' (ADMA) quarterly EBIT Margin came in at 45.09% in Q4 2025, up 1249.0% YoY from 3.34% in Q4 2024, and up 18.65% on a QoQ basis from 38.01% in Q3 2025.
Adma Biologics (ADMA) EBIT Margin (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of EBIT Margin data on file, last reported at 45.09% in Q4 2025.
- Quarterly EBIT Margin rose 1249.0% year-over-year to 45.09% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 37.52% (up 493.0% YoY) and the FY2025 annual result came in at 37.53%, up 493.0% from the prior year.
- EBIT Margin advanced to 45.09% in Q4 2025, from 38.01% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 45.09% in Q4 2025 to a low of 94.49% in Q1 2021.
- A 5-year average of 3.56% and a median of 3.55% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2021 — EBIT Margin surged 13250 bps — and 2025, when it plunged 149 bps.
- Tracing ADMA's EBIT Margin over 5 years: stood at 23.98% in 2021, then soared by 49 bps to 12.12% in 2022, then surged by 259 bps to 19.26% in 2023, then soared by 69 bps to 32.6% in 2024, then soared by 38 bps to 45.09% in 2025.
- The last three EBIT Margin figures came in at 45.09% (Q4 2025), 38.01% (Q3 2025), and 35.08% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 42.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.16% |
| Dec 31, 2025 | 45.09% |
| Sep 30, 2025 | 38.01% |
| Jun 30, 2025 | 35.08% |
| Mar 31, 2025 | 30.38% |
| Dec 31, 2024 | 32.60% |
| Sep 30, 2024 | 33.08% |
| Jun 30, 2024 | 36.57% |
| Mar 31, 2024 | 26.65% |
| Dec 31, 2023 | 19.26% |
| Sep 30, 2023 | 7.90% |
| Jun 30, 2023 | -0.79% |
| Mar 31, 2023 | -1.43% |
| Dec 31, 2022 | -12.12% |
| Sep 30, 2022 | -22.67% |
| Jun 30, 2022 | -12.23% |
| Mar 31, 2022 | -50.91% |
| Dec 31, 2021 | -23.98% |
| Sep 30, 2021 | -69.81% |
| Jun 30, 2021 | -87.38% |